• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Osteosarcoma Growth in Mice Drives Adipose Loss Linked to Elevated FGF21

by
November 11, 2026
in Cancer, Health
Reading Time: 6 mins read
0
Osteosarcoma Growth in Mice Drives Adipose Loss Linked to Elevated FGF21

Osteosarcoma Growth in Mice Drives Adipose Loss Linked to Elevated FGF21

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In a newly published investigation exploring systemic metabolic dysfunction during malignant bone tumor progression, researchers have demonstrated that osteosarcoma driven by the overexpression of the AP-1 transcription factor family member Fos causes marked cachexia-like adipose wasting and muscle loss in mice. The study, conducted by Julia Luther, Thorsten Schinke, and their colleagues, established that ubiquitous overexpression of the Fos proto-oncogene under the H2Kb promoter induces the development of osteosarcomas with complete penetrance while simultaneously triggering a severe reduction in fat mass and body weight. Rather than stemming from a primary, cell-intrinsic defect in adipogenesis, this metabolic deterioration was accompanied by elevated circulating concentrations of fibroblast growth factor 21, an endocrine hormone involved in energy expenditure and nutrient handling. By employing both proteomic profiling and genetic manipulation to alter tumor development, the authors demonstrated that the systemic loss of adipose tissue and the surge in circulating Fgf21 depend directly on osteosarcoma burden, revealing a distinct functional link between skeletal tumor growth and cachexia-associated metabolic disruption.

Cancer cachexia is a multifaceted catabolic syndrome that affects up to eighty percent of human cancer patients, manifesting as progressive depletion of skeletal muscle, adipose stores, and overall body mass that cannot be restored through supplemental caloric nutrition alone. Members of the dimeric AP-1 transcription factor family, formed through heterodimerization or homodimerization between Fos and Jun proteins, have long been recognized as regulators of bone remodeling, cellular transformation, and adipose biology. Previous studies indicated that while overexpression of related proteins such as Fra1 or DeltaFosB influences bone formation and fat accumulation, Fos uniquely transforms chondro-osteoblastic lineages postnatally in mice, generating widespread osteosarcomas from two to three weeks of age. The current research aimed to dissect whether the marked reduction in body weight observed in these transgenic animals represented an independent metabolic activity of Fos or a secondary metabolic manifestation driven by skeletal tumorigenesis.

Phenotypic characterization of the Fos transgenic cohort revealed that adult mutant mice remained consistently smaller and leaner than their non-transgenic wild-type littermates across an aging period monitored from eight to twenty-two weeks. Quantitative dissection of specific anatomical depots demonstrated a generalized loss of fat mass, with substantial weight reductions documented in epididymal, subcutaneous posterior, and perirenal white adipose tissues, as well as in interscapular brown adipose tissue. Histomorphometric measurements of epididymal fat pads further showed that while adipocyte diameter distributions were relatively comparable between mutant and control animals at eight weeks of age, transgenic adipocytes completely failed to undergo the progressive cell size expansion typically observed during normal adult maturation. Despite this pronounced cellular shrinkage, quantitative real-time PCR profiling of white adipose tissue demonstrated normal expression levels of the primary transcriptional drivers of adipocyte commitment and differentiation, including Cebpb, Cebpd, Cebpa, and Pparg, along with mature adipocyte markers such as Fabp4 and Glut4.

To definitively exclude the possibility that ubiquitous Fos expression caused a cell-autonomous defect preventing adipocyte progenitor differentiation, the research team isolated adipose-derived stem cells directly from the subcutaneous depots of adult mice. Cellular growth assays over a seven-day culture window indicated no intrinsic defects in proliferation kinetics or spontaneous apoptosis. Progenitor responsiveness to critical adipogenic cues was thoroughly preserved, as demonstrated by the normal phosphorylation of Creb following stimulation with isobutylmethylxanthine, intact extracellular signal-regulated kinase activation in response to insulin, and the robust induction of the glucocorticoid target genes Gilz1 and Per1 upon dexamethasone exposure. When placed under adipogenic differentiation cocktails containing insulin, dexamethasone, and isobutylmethylxanthine, stem cells from both wild-type and transgenic animals accumulated equivalent amounts of neutral lipids as measured by Oil Red O staining. Expression dynamics of adipogenic markers across differentiation confirmed that the physiological capacity of mesenchymal precursors to form mature, lipid-storing adipocytes remained unimpaired in transgenic tissues.

Because intrinsic cellular failure was ruled out, the researchers investigated systemic humoral axes that coordinate communication between skeletal tissues, the pancreas, and adipose reservoirs in sixteen-week-old animals. Transgenic mice exhibited significantly reduced circulating leptin concentrations under both fed and starved states, consistent with their profoundly diminished total fat content. Circulating levels of total osteocalcin, an osteoblast-secreted hormone known to modulate beta-cell proliferation and glucose metabolism, were markedly elevated in transgenic serum, presumably produced by the expanded osteosarcoma lesions. However, pancreatic histological analysis revealed that the proportionate surface area occupied by insulin-positive beta-cell islets was indistinguishable between wild-type and transgenic cohorts. Furthermore, basal circulating insulin levels remained unaffected, demonstrating appropriate physiological declines during food deprivation. Strikingly, systemic glucose concentrations in transgenic mice were significantly depressed in the fed state and failed to exhibit the standard fasting drop, suggesting altered peripheral glucose homeostasis.

To uncover the molecular mediators responsible for driving this altered metabolic state, the investigators performed a broad proteomic screen measuring the relative abundance of approximately fourteen hundred proteins in pooled serum samples using an antibody microarray platform. Pathway enrichment analysis identified prominent perturbations in cancer-related cascades, tumor necrosis factor signaling, and mitogen-activated protein kinase networks. Several secreted factors known to participate in catabolic syndromes, including Tnfsf10, colony-stimulating factor 1, transforming growth factor alpha, and hepatocyte growth factor, were elevated in transgenic sera. Most prominently, the screen identified a pronounced elevation in fibroblast growth factor 21, a finding validated through quantitative enzyme-linked immunosorbent assays. Tissue-specific expression analyses via quantitative reverse transcription PCR showed that while wild-type mice expressed Fgf21 predominantly within the liver, transgenic animals displayed significant transcript upregulation across brown adipose tissue, the liver, and within the osteosarcoma tumors themselves, with the highest expression concentrated in hepatic and neoplastic tissues.

The elevated presence of Fgf21 closely aligned with the classical muscular and energetic features of cancer cachexia observed in the mutant animals. Anatomical evaluation showed that transgenic mice experienced a significant loss of skeletal muscle mass, evidenced by reduced quadriceps weight, accompanied by a modest decrease in cardiac weight. Comprehensive metabolic cage monitoring of food intake at eight and sixteen weeks of age demonstrated that this somatic wasting was not a consequence of hypophagia or anorexia, as daily nutrient consumption was comparable between genotypes. In subcutaneous white adipose tissue, histological examination revealed extensive adipocyte shrinkage paired with a marked transcriptional upregulation of the thermogenic markers uncoupling protein 1 and Cidea, indicating enhanced white adipose tissue browning. When subjected to dynamic metabolic tolerance testing, sixteen-week-old transgenic mice exhibited accelerated blood glucose clearance following an intraperitoneal glucose challenge and heightened peripheral sensitivity following exogenous insulin administration, matching known physiological consequences of augmented systemic Fgf21 activity.

Because Fgf21 acts as a key hepatic endocrine signal that restrains de novo fatty acid synthesis and promotes metabolic remodeling, the investigators next conducted detailed biochemical analyses of liver tissue from sixteen-week-old mice. Transgenic animals exhibited hepatic expression of the Fos transgene and a marked increase in total Fos protein, yet histological inspection of liver sections revealed no lipid accumulation, steatosis, or differences in total tissue weight and glycogen stores. In serum, non-esterified fatty acid levels were unaltered, but circulating triglyceride concentrations were sharply reduced in transgenic mice. Quantitative expression analysis demonstrated stable levels of transcriptional regulators controlling mitochondrial beta-oxidation, such as Ppara and Cpt1a, but revealed a pronounced down-regulation of essential enzymes governing hepatic lipogenesis, including thyroid hormone-responsive spot 14, ATP citrate lyase, fatty acid synthase, and elongation of very long chain fatty acids protein 6. Western blot analyses showed decreased phosphorylation of signal transducer and activator of transcription 3 and elevated phosphorylation of Smad2, further supporting altered hepatic signaling downstream of elevated Fgf21.

To establish whether the cachexia-like phenotype and hormonal elevation were causally linked to skeletal tumor development, the authors crossed Fos transgenic animals with mice harboring a genetic deletion of ribosomal S6 kinase 2, a kinase required for Fos-driven transformation. Inactivation of Rsk2 in the FosTg;Rsk2-/y line resulted in a substantial decrease in osteosarcoma progression, as confirmed by skeletal radiographic analyses. At sixteen weeks of age, Rsk2-deficient transgenic mice exhibited significantly ameliorated somatic wasting, displaying body weights and epididymal fat pad masses that were considerably higher than those of tumor-bearing FosTg counterparts. Histomorphometric quantification confirmed that adipocyte diameters in double-mutant mice were intermediate between wild-type controls and FosTg animals. Crucially, circulating Fgf21 levels were significantly reduced in FosTg;Rsk2-/y mice compared to standard Fos transgenic littermates, and a direct linear correlation was identified between serum Fgf21 concentrations and the quantified tumor area measured within vertebral bodies across the mouse cohort.

The study provides critical experimental evidence that Fos-induced osteosarcoma acts remotely to reprogram systemic lipid and carbohydrate metabolism, highlighting circulating Fgf21 as a major biomarker and potential driver of tumor-associated adipose wasting. However, the authors emphasize several notable experimental boundaries, including the fact that correlative measurements cannot entirely rule out contributions from other secreted cachectic factors, nor can they definitively prove whether elevated Fgf21 serves primarily as a pathological driver of wasting or represents a protective compensatory attempt by stressed tissues to maintain energetic equilibrium. Future interventional investigations utilizing targeted genetic deletions of Fgf21 or pharmacological receptor antagonists will be necessary to resolve the exact causal mechanism. In addition, determining the precise relative contribution of tumor-derived versus liver-derived Fgf21 secretion remains an essential step toward uncovering potential therapeutic opportunities for treating cancer-associated metabolic wasting.

Subject of Research: Tumor-induced metabolic alterations and cachexia-like adipose tissue wasting in Fos transgenic osteosarcoma mouse models

Article Title: Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels

Article References: Luther, J., Carreau, A., Baldauf, C., Neven, M., Koehne, T., Amling, M., & Schinke, T. (2026). Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels. Cancer & Metabolism, 14(1), Article 18. https://doi.org/10.1186/s40170-025-00417-y

Image Credits: AI Generated

DOI: 10.1186/s40170-025-00417-y

Keywords: Osteosarcoma, Fos, Fgf21, Cancer cachexia, Adipose tissue wasting, White adipose tissue, Brown adipose tissue, Glucose tolerance, Insulin sensitivity, Hepatic lipogenesis, Rsk2 kinase, Transgenic mice, AP-1 transcription factor, Triglycerides, Adipocyte size, Ucp1, Cidea, Tumor burden

News Source: Nathaniel Bowman. (November 11, 2026). Osteosarcoma Growth in Mice Drives Adipose Loss Linked to Elevated FGF21. Scienmag.

Tags: Adipocyte sizeAdipose tissue wastingAP-1 transcription factorbrown adipose tissuecancer cachexiaCideaFGF21FOSglucose toleranceHepatic lipogenesisInsulin SensitivityOsteosarcomaRsk2 kinasetransgenic micetriglyceridesTumor BurdenUCP1white adipose tissue
Share12Tweet7Share2ShareShareShare1

Related Posts

HIV and Tuberculosis Co-Infection Rates Dropped in Liangshan Between 2019 and 2024

HIV and Tuberculosis Co-Infection Rates Dropped in Liangshan Between 2019 and 2024

November 18, 2026
Behavior Setting Theory Guides Blood Pressure Monitoring Adaptation Across Different Healthcare Contexts

Behavior Setting Theory Guides Blood Pressure Monitoring Adaptation Across Different Healthcare Contexts

November 18, 2026

Short-Video Shopping Predicts Distress Through Compulsive Buying When Emotionally Motivated

November 18, 2026

Review Links SFTS Virus Immune Evasion to Clinical Treatment Hurdles

November 18, 2026

POPULAR NEWS

  • Neural Network Inverse Design Optimizes Broadband Hybrid Plasmonic Leaky Wave Antenna

    Neural Network Inverse Design Optimizes Broadband Hybrid Plasmonic Leaky Wave Antenna

    29 shares
    Share 12 Tweet 7
  • Livestock Holdings and Agroecology Shape Carnivore Conservation Attitudes in Southern Ethiopia

    29 shares
    Share 12 Tweet 7
  • Researchers Identify GRAM Genes Across Cultivated Sweetpotato and Two Diploid Relatives

    29 shares
    Share 12 Tweet 7
  • Sensor Weighted Crop Simulations Significantly Improve Drone Maize Leaf Area Retrieval

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Simulated DNN-Enhanced Precoding Boosts Cell-Free Massive MIMO SINR by 12 dB

HIV and Tuberculosis Co-Infection Rates Dropped in Liangshan Between 2019 and 2024

Multiomics Analysis Uncovers Genetic Networks Driving Kiwifruit Ripening and Flavor Formation

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.